false
0001476963
0001476963
2024-04-29
2024-04-29
0001476963
us-gaap:CommonStockMember
2024-04-29
2024-04-29
0001476963
SCPX:CommonStockPurchaseRightsMember
2024-04-29
2024-04-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
April 29, 2024
Scorpius Holdings, Inc.
(Exact name of registrant as specified in
charter)
Delaware
(State or other jurisdiction of incorporation)
001-35994 |
26-2844103 |
(Commission File Number) |
(IRS Employer Identification No.) |
627
Davis Drive, Suite
400
Morrisville, North Carolina 27560
(Address of principal executive offices and
zip code)
(919) 240-7133
(Registrant’s telephone number including
area code)
(Former Name and Former Address)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.0002 par value per share |
SCPX |
NYSE American LLC |
Common Stock Purchase Rights |
None |
NYSE American LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨ |
|
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On
April 29, 2024, Scorpius Holdings, Inc., a Delaware corporation (the “Registrant”), issued the attached press release that
included financial information for its fiscal year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K.
The
information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed with this Current
Report on Form 8-K:
Exhibit Number |
|
Description |
99.1 |
|
Press release dated April 29, 2024 |
104 |
|
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 29, 2024 |
SCORPIUS HOLDINGS, INC. |
|
|
|
|
|
|
By: |
/s/ Jeffrey Wolf |
|
Name: |
Jeffrey Wolf |
|
Title: |
Chairman, President and Chief Executive Officer |
Exhibit 99.1
Scorpius Holdings Provides 2023 Year-End
Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023
Durham, NC – April 29, 2024 –Scorpius
Holdings, Inc (NYSE American: SCPX) (‘Scorpius” or “the Company”), an integrated contract development
and manufacturing organization providing state-of-the-art large molecule contract development and manufacturing organization (“CDMO”),
today provided strategic, financial, and operational updates for the year ended December 31, 2023.
Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “We
are executing our plan to augment sales and drive revenue, as evidenced by the $4.8 million of revenue from continuing operations that
we reported in the fourth quarter of 2023. This represents a 570% increase from the third quarter of 2023, and a 226% increase compared
to revenue for the first nine months of the year. To date, Scorpius’s successful business development efforts have resulted in the
recording of more than $20 million of contract bookings. We believe our bookings, coupled with the strong interest in our microbial and
mammalian capabilities and promising pipeline of new opportunities, positions us well for significant growth in 2024 and beyond.”
"As the large molecule drug substance CDMO market is
projected to grow from $10 billion in 2023 to $21 billion by 20301, there is a substantial need for enhanced industry capacity.
With our scalable business model and the rising demand for our large molecule CDMO services, we believe that we are well-positioned to
capture a meaningful share of this market. Moreover, we expect Scorpius’ growth to accelerate in 2024 and remain optimistic about
becoming cash flow positive by early 2025. With the completion of our facility and divestiture of our research and non-core assets, we
substantially reduced our operating expenses in the fourth quarter of 2023. As a result, we believe the future for Scorpius could not
be brighter as our 60,000+ sq. ft. campus provides us sufficient capacity to grow our business with minimal additional capex requirements,
which we believe is the key to maximizing profits and returns for our shareholders,” concluded Mr. Wolf.
2023 Financial Results
• For the year ended December 31, 2023, the Company
recognized $6.6 million of contract revenue, $0.3 million of National Institutes of Health grant revenue, and $0.1 million of royalty
revenue from continuing operations. For the year ended December 31, 2022, revenue consisted of $0.1 million of contract revenue and $0.3
million of CPRIT grant revenue from continuing operations. The revenue does not reflect any revenue derived from Elusys Therapeutics which
was divested in December 2023 and reported in discontinued operations. The increase in contract revenue is primarily due to the execution
of process development contracts, a substantial portion of which was from one customer, from which we no longer anticipate deriving significant
revenue.
• For the year ended December 31, 2023, the
Company recognized $2.7 million of cost of revenues from product sales as compared to $0.1 million for the year ended December 31, 2022.
The increase of $2.6 million was due to the cost of executing on process development contracts.
• Selling, general and administrative expenses for
the years ended December 31, 2023, and 2022 were $26.2 million and $20.1 million, respectively. The increase of $6.1 million was primarily
due to increased sales and marketing costs for marketing the Company to the CDMO market space of $2.4 million, an increase in labor for
Scorpius to support operations of $1.8 million, an increase in legal, accounting, and other professional expenses to manage the business
of $1.8 million, an increase in facilities expenses from the opening of our San Antonio facility of $1.4 million, an increase in depreciation
and amortization of $0.8 million due to increased investment in equipment and the amortization of right to use assets, offset by decreases
in stock-based compensation of $1.1 million, a decrease in other facility and operation expenses of $0.4 million, a reduced need for outside
consultants associated with the build-out of Scorpius of $0.4 million, and a reduction of insurance costs of $0.1 million.
• In-process research and development (“IPR&D”)
impairment was $0 and $3.5 million for the years ended December 31, 2023, and 2022, respectively. IPR&D was fully impaired during
the third quarter of 2022 as the PTX-35 trial did not progress to Phase 2.
• Net loss attributable to Scorpius was approximately
$45.2 million, or ($1.74) per basic and diluted share, for the year ended December 31, 2023, compared to approximately $43.4 million,
or ($1.70) per basic and diluted share, for the year ended December 31, 2022.
• As of December 31, 2023, the Company had approximately
$2.4 million in cash, cash equivalents, and short-term investments.
Pursuant to the disclosure requirements of the NYSE American
Company Guidelines Sections 401(h) and 610(b), Scorpius reports that its audited financial statements for the year ended December 31,
2023 and 2022, included in its 2023 annual report on Form 10-K, contain an audit opinion from its independent registered public accounting
firm that includes an explanatory paragraph related to the Company’s ability to continue as a going concern due to the fact that
the Company has suffered recurring losses from operations and has not generated significant revenue or positive cash flows from operations.
_________________________
1 SkyQuest Large Molecule Industry Forecast,
February 2024
Scorpius
Holdings, Inc.
Scorpius Holdings
Inc. is an integrated CDMO focused on manufacturing biologic and cell therapy programs for our clients. Scorpius offers a broad array
of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration
and flexible, high-quality biologics biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking
Statement
This
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases,
forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes," "estimates," and
similar expressions, and include statements such as
the bookings, coupled with the strong interest
in the Company’s microbial and mammalian capabilities and promising pipeline of new opportunities, positions it well for significant
growth in 2024 and beyond; the large molecule drug substance CDMO market projected growth from $10 billion in 2023 to $21 billion by 2030;
being well-positioned to capture a meaningful share of the market; Scorpius’ growth accelerating in 2024 and becoming cash flow
positive by early 2025; the future for Scorpius could not be brighter as its 60,000+ sq. ft. campus provides it sufficient capacity to
grow its business with minimal additional capex requirements, and maximizing profits and returns for its shareholders.
Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s
ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its bookings and continue to grow
revenue; the ability to capture a meaningful market share; he ability to become cash flow positive; the Company’s financing needs,
its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage
fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing
regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete
as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023,
subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation
is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained
in this presentation on account of new information, future events, or otherwise, except as required by law.
Media
and Investor Relations Contact
David
Waldman
+1 919
289 4017
ir@scorpiusbiologics.com
v3.24.1.u1
Cover
|
Apr. 29, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Apr. 29, 2024
|
Entity File Number |
001-35994
|
Entity Registrant Name |
Scorpius Holdings, Inc.
|
Entity Central Index Key |
0001476963
|
Entity Tax Identification Number |
26-2844103
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
627
Davis Drive
|
Entity Address, Address Line Two |
Suite
400
|
Entity Address, City or Town |
Morrisville
|
Entity Address, State or Province |
NC
|
Entity Address, Postal Zip Code |
27560
|
City Area Code |
(919)
|
Local Phone Number |
240-7133
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock [Member] |
|
Common Stock |
Common Stock, $0.0002 par value per share
|
Trading Symbol |
SCPX
|
Security Exchange Name |
NYSEAMER
|
Common Stock Purchase Rights [Member] |
|
Common Stock |
Common Stock Purchase Rights
|
Trading Symbol |
None
|
Security Exchange Name |
NYSEAMER
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=SCPX_CommonStockPurchaseRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2024 to May 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From May 2023 to May 2024